Fiche publication
Date publication
juin 2016
Journal
Targeted oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BOIDOT Romain
,
Pr HARLE Alexandre
,
Dr LEROUX Agnès
,
Pr MERLIN Jean-Louis
Tous les auteurs :
Harlé A, Filhine-Tresarrieu P, Husson M, Boidot R, Rouyer M, Dubois C, Leroux A, Merlin JL
Lien Pubmed
Résumé
Overall survival of metastatic colorectal cancer (mCRC) patients has been improved with the addition of targeted therapy such as anti-epithelial growth factor receptor monoclonal antibodies (anti-EGFR mAbs) to standard chemotherapy. Retrospective studies and randomized trials showed that the presence of RAS mutations was linked to the absence of clinical response to anti-EGFR mAbs. Patients harboring KRAS and NRAS mutations on exons 2, 3 or 4 have little or no benefit from anti-EGFR therapies. Polymerase chain reaction (PCR)-based assays are routinely used to assess KRAS and NRAS status, whereas deep sequencing with next generation sequencing (NGS) currently represents an alternative method.
Mots clés
Colorectal Neoplasms, drug therapy, Genes, ras, genetics, Genotype, High-Throughput Nucleotide Sequencing, methods, Humans, Mutation, Neoplasm Metastasis, Survival Analysis
Référence
Target Oncol. 2016 Jun;11(3):363-70
